CADL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Candel Therapeutics
Candel pointed investors to a fourth-quarter 2026 BLA submission for aglatimagene as recently as August 13, 2026. On November 12, that target moved to mid-2027, CADL fell more than 26% the following day, and shareholders who lost money may have rights to recover. NEW YORK, Nov. 17, 2026...